Perspektiven des metabolischen Syndroms bei Kindern und Jugendlichen

Zusammenfassung

Mit der steigenden Prävalenz von Adipositas im Kindes-und Jugendalter erhöht sich die Prävalenz entsprechender Komorbiditäten wie Hypertonie, Dyslipidämie und gestörter Glukosetoleranz. Einige Autoren sehen die Insulinresistenz als ursächlichen Faktor für die genannten Störungen an. Zur endgültigen Abklärung der zugrunde liegenden Pathomechanismen bedarf es jedoch noch weiterer Studien. Bei der Analyse möglicher ursächlicher Faktoren aus dem Fettgewebe fanden bisher vor allem Leptin und Adiponektin große Beachtung. Es herrscht weiterhin Uneinigkeit über die genaue Definition des metabolischen Syndroms bei Kindern. Entsprechend aktueller Untersuchungen sollten die bestehenden Definitionen um die nichtalkoholisch bedingte Steatohepatitis erweitert werden. Ungeachtet einer fehlenden einheitlichen Definition besteht jedoch kein Zweifel an der Notwendigkeit einer engen Verlaufsbeobachtung adipöser Kinder und einer frühen therapeutischen Intervention sich aufzeigender Komorbiditäten.

Summary

The increasing prevalence of obesity in children and adolescents results ina raised prevalence of corresponding comorbidities like hypertension, dyslipidemia and impaired glucose tolerance. Few authors regard the insulin resistance as being causal for these sequelae. In respect of the underlying pathomechanisms there is an additional demand on studies. At the previous analyses of causal factors deriving from the adipose tissue Leptin and Adiponectin gain special attention. Furthermore there is a discordance about the exact definition of the metabolic syndrome in children. Ongoing research lead to the hypothesis, that the present definition of the metabolic syndrome should be extended by the nonalcoholic steatohepatitis. Regardless the currently unavailable consistent definition of the metabolic syndrome there is no doubt of the necessity fora frequent observation of obese children and an early therapeutic intervention of emerging comorbidities.

Schlüsselwörter

Metabolisches Syndrom - Adipozytokine - Diabetes - Steatohepatitis

Keywords

Metabolic syndrome - adipozytokines - diabetes - steatohepatitis

• Literatur

• 1 National Cholesterol Education Programm (NCEP) Expert Panel on Detektion, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) 2002. Third Report of National Cholesterol Education Program (NCEP) Expert Panel on Detektion, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), final report. Circulation 2007; 106: 3143-3421.
• 2 Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report ofa WHO consultation. Diabet Med 1998; 15 (07) 539-553.
• 3 Berenson GS. Obesity - a critical issue in preventive cardiology: the Bogalusa Heart Study. Prev Cardiol 2005; 08 (04) 234-241.
• 4 Bottner A, Kratzsch J, Muller G. et al. Gender differences of adiponectin levels develop during the progression of puberty and are related to serum androgen levels. J Clin Endocrinol Metab 2004; 89 (08) 4053-4061.
• 5 Chan DF, Li AM, Chu WC. et al. Hepatic steatosis in obese Chinese children. Int J Obes Relat Metab Disord 2004; 28 (10) 1257-1263.
• 6 Chu NF, Shen MH, Wu DM, Lai CJ. Relationship between plasma adiponectin levels and metabolic risk profiles in Taiwanese children. Obes Res 2005; 13 (11) 2014-2020.
• 7 de Ferranti SD, Gauvreau K, Ludwig DS. et al. Prevalence of the metabolic syndrome in American adolescents: findings from the Third National Health and Nutrition Examination Survey. Circulation 2004; 110 (16) 2494-2497.
• 8 de Ferranti SD, Gauvreau K, Ludwig DS. et al. Inflammation and changes in metabolic syndrome abnormalities in US adolescents: findings from the 1988-1994 and 1999-2000 National Health and Nutrition Examination Surveys. Clin Chem 2006; 52 (07) 1325-1330.
• 9 Flier JS. Clinical review 94: What’s ina name? In search of leptin’s physiologic role. J Clin Endocrinol Metab 1998; 83 (05) 1407-1413.
• 10 Grundy SM, Cleeman JI, Daniels SR. et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112 (17) 2735-2752.
• 11 Gura T. Obesity research. Leptin not impressive in clinical trial. Science 1999; 286 (5441): 881-882.
• 12 Halaas JL, Gajiwala KS, Maffei M. et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995; 269 5223): 543-546.
• 13 Hara K, Yamauchi T, Kadowaki T. Adiponectin: an adipokine linking adipocytes and type 2 diabetes in humans. Curr Diab Rep 2005; 05 (02) 136-140.
• 14 Hauner H. Secretory factors from human adipose tissue and their functional role. Proc Nutr Soc 2005; 64 (02) 163-169.
• 15 Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005; 26 (03) 439-451.
• 16 Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28 (09) 2289-2304.
• 17 Keller E, Gausche R, Meigen C. et al. Auxological computer based network for early detection of disorders of growth and weight attainment. J Pediatr Endocrinol Metab 2002; 15 (02) 149-156.
• 18 Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89 (06) 2548-2556.
• 19 Kiess W, Galler A, Reich A. et al. Clinical aspects of obesity in childhood and adolescence. Obes Rev 2001; 02 (01) 29-36.
• 20 Kiess W, Gausche R, Keller A. et al. Computer-guided, population-based screening system for growth disorders (CrescNet) and on-line generation of normative data for growth and development. Horm Res 2001; 56 (Suppl. 01) 59-66.
• 21 Koerner A, Kratzsch J, Kiess W. Adipocytokines: leptin- the classical, resistin - the controversical, adiponectin - the promising, and more to come. Best Pract Res Clin Endocrinol Metab 2005; 19 (04) 525-546.
• 22 Kurth BM, Schaffrath RA. The prevalence of overweight and obese children and adolescents living in Germany. Results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2007; 50 (5–6): 736-743.
• 23 Lambert M, Paradis G, O’loughlin M. et al. Insulin resistance syndrome in a representative sample of children and adolescents from Quebec, Canada. Int J Obes Relat Metab Disord 2004; 28 (07) 833-841.
• 24 Lavine JE, Schwimmer JB. Nonalcoholic fatty liver disease in the pediatric population. Clin Liver Dis 2004; 08 (03) 549-558.
• 25 Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37 (12) 1595-1607.
• 26 Reich A, Muller G, Gelbrich G. et al. Obesity and blood pressure - results from the examination of 2365 schoolchildren in Germany. Int J Obes Relat Metab Disord 2003; 27 (12) 1459-1464.
• 27 Reinehr T, Andler W, Denzer C. et al. Cardiovascular risk factors in overweight German children and adolescents: relation to gender, age and degree of overweight. Nutr Metab Cardiovasc Dis 2005; 15 (03) 181-187.
• 28 Reinehr T, Roth C, Menke T, Andler W. Adiponectin before and after weight loss in obese children. J Clin Endocrinol Metab 2004; 89 (08) 3790-3794.
• 29 Reinehr T, Wabitsch M, Andler W. et al. Medical care of obese children and adolescents. APV: a standardised multicentre documentation derived to study initial presentation and cardiovascular risk factors in patients transferred to specialised treatment institutions. Eur J Pediatr 2004; 163 (06) 308-312.
• 30 Siebler J, Galle PR. Treatment of nonalcoholic fatty liver disease. World J Gastroenterol 2006; 12 (14) 2161-2167.
• 31 Sinha R, Fisch G, Teague B. et al. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med 2002; 346 (11) 802-810.
• 32 Weiss R, Dziura J, Burgert TS. et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004; 350 (23) 2362-2374.
• 33 Wiegand S, Maikowski U, Blankenstein O. et al. Type 2 diabetes and impaired glucose tolerance in European children and adolescents with obesity - a problem that is no longer restricted to minority groups. Eur J Endocrinol 2004; 151 (02) 199-206.
• 34 Zhang Y, Proenca R, Maffei M. et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372 (6505): 425-432.
• 35 Zou CC, Liang L, Hong F. et al. Serum adiponectin, resistin levels and non-alcoholic fatty liver disease in obese children. Endocr J 2005; 52 (05) 519-524.